Similarly, Banerjee et al.’s (2014) research group intra-arterially infused (via the MCA) 10 million autologous sorted CD34+ cells in five patients within 1–7 days of stroke onset, and found the intervention to be safe, and associated with a decrease in infarct size over time. This evidence concerns the gene CD34 and stroke disorder.